Global animal health company Huvepharma's Optigrid® 45, ractopamine hydrochloride Type A medicated article a feed additive used to promote weight gain and improve feed efficiency in finishing feedlot cattle, has received U.S. Food & Drug Administration (FDA) approval for combination use with other drug feed additive products in the manufacture of Type B and C medicated feeds.
Optigrid® 45, which is comprised of the active ingredient ractopamine hydrochloride, can be fed as a complete feed or top dress feed to cattle fed in confinement for slaughter during the last 28-48 days on feed prior to harvest. The combination approvals allow Optigrid® 45 to be used with other feed additives commonly fed to feedlot cattle, including monensin, tylosin and melengestrol.
The four specific combinations receiving FDA approval include
- Optigrid® 45 with Monovet® 90 (monensin Type A medicated article)
- Optigrid® 45 with Monovet® 90 and Tylovet® (tylosin phosphate Type A medicated article)
- Optigrid® 45 with Monovet® 90 and MGA® (melengestrol)
- Optigrid® 45 with Monovet® 90, Tylovet® and MGA®
"With the continued need for efficiency in beef production, we are pleased to bring these medicated feed additive combinations with Optigrid® 45 to the cattle industry," said head of U.S. sales and marketing, Rick Cozzitorto.
Huvepharma has been active in the U.S. animal health market since 2005 providing products for poultry, swine and cattle markets. The company received FDA approval for Optigrid® 45 in June 2020.
For more information, please contact your Huvepharma sales representative and/or Huvepharma's U.S. customer service team by calling +1 877-994-4883.
